The administration yesterday withdrew the Health Resources and Services Administration’s pending omnibus guidance for the 340B Drug Pricing Program. “We are pleased that the Administration chose not to finalize the Health Resources and Services Administration’s guidance, which, if enacted would have jeopardized hospitals’ ability to serve vulnerable populations, including low-income and uninsured individuals and patients receiving cancer treatments,” said AHA Executive Vice President Tom Nickels. AHA previously expressed strong concerns regarding HRSA’s proposed policy changes, stating that re-defining 340B patient eligibility would have narrowed inappropriately the number of drugs that qualify for 340B pricing and threatened access to care for patients who need it the most. In addition, AHA objected to HRSA’s proposals regarding infusion services, and urged that patients receiving infusion services provided at 340B hospitals or their outpatient sites be allowed to continue to qualify for 340B drug discount pricing. 

Related News Articles

Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 issued a memo, through the Health Plan Management system, finalizing the Medicare Advantage…
Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The AHA Sept. 29 sent recommendations to the Department of Health and Human Services and the Centers for Medicare & Medicaid Services to help ensure…